Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that researchers will present the results of 11 scientific poster presentations involving the company's consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry's Meeting e-posters Virtual Event, which is taking place from June 13-14, 2023. In.

Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting

Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.

Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA

Markets overreacted to Norwich suing the FDA. Investors must consider recently reported weak Q1 results of Bausch Health. Reasons BHC stock is a buy from here.

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Today, Bausch Health Company acknowledged the FDA's decision to tentatively approve a generic version of Xifaxan. The company also noted that final approval remains off the table until Oct. 2, 2029.

Why Bausch Health Companies Stock Is Tanking Today

LAVAL, QC / ACCESSWIRE / June 6, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg. At the same time, the FDA confirmed in its Letter that it cannot grant Final Approval until Oct. 2, 2029 - the date specified by the presiding judge in his Final Judgment in Salix Pharmaceuticals, LTD et al.

Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Biotrue® Hydration Boost Contact Lens Rehydrating drops, the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to lubricate and rewet soft contact lenses, including daily disposables, and rigid gas permeables. “We're proud to build on.

Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE® Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology™ for all-day comfort and the company's unique 3-Zone Progressive™ design, the new lens addresses the dynamic visi.

Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the Company reporting directl.

Bausch + Lomb Announces Key Leadership Changes

Cover Your Bases Campaign Kicks Off Oral Health Month with ARESTIN (minocycline HCI) Patient Ambassador Alex Rodriguez LAVAL, QC , May 31, 2023 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover Your Bases campaign includes educational content about the disease and encourages patients to talk to their dentist about comprehensive treatment options.

OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich

VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--FDA approves MIEBO (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease.

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Novel Trial to Study the Reduction of Certain Pathogens Following Scaling and Root Planing Procedure LAVAL, QC / ACCESSWIRE / May 18, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its oral health care business, OraPharma, today announced the publication of a new study, which showed that ARESTIN® (minocycline HCI) microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults with periodontitis when applied immediately after scaling and root planning (SRP) and again at a three-month reapplication, versus SRP alone. ARESTIN is an FDA-approved antibiotic applied locally to gum pockets in adults with periodontitis following an SRP procedure and is used as part of an overall oral health program.

New Clinical Study Suggests the Use of OraPharma's ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis

Bausch Health Cos. Inc. BHC, +24.09% on Wednesday said a U.S. district court stuck with an earlier judgment that prevented an application for a rival generic version of its Xifaxan irritable bowel syndrome drug from getting FDA approval until 2029, sending shares higher during regular and after-hours trade.

Bausch Health stock soars after company says rival application for generic version of its IBS drug can't be approved until 2029

Bausch could get to keep its patent for an IBS drug for another six years. The drug brought in nearly $400 million in the first quarter.

Why Shares of Bausch Health Soared Wednesday

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals' motion to modify the Court's final judgment that prevents the U.S. Food and Drug Administration (FDA) from approving Norwich's abbreviated new drug application (ANDA) for XIFAXAN® (rifaximin) 550 mg before Oct. 2, 2029.

U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2023 annual meeting of shareholders (the "Annual Meeting"). The 10 directors nominated at the Company's Annual Meeting held on May 16, 2023, were elected by a vote of the Company's shareholders.

Bausch Health Announces 2023 Annual Meeting of Shareholder Results

Bausch Health has been through rough times, leading to skepticism among investors. Its investment potential, however, has been on the upswing since 2016, when Joseph Papa took over as CEO.

Bausch Health: Bullish On Long-Term Prospects, Awaiting Subsiding Headwinds

LAVAL, QC / ACCESSWIRE / May 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs. With more people finding value in speaking with a mental health professional and seeking treatment, this heightened focus on mental health has never been more important.1 By the end of 2022, 37% of Americans rated their mental health as "fair or poor"-a 6% increase from 2021.

Bausch Health Observes Mental Health Awareness Month

Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be Presented LAVAL, QC / ACCESSWIRE / May 8, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), the gastroenterology (GI) business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and one of the largest specialty pharmaceutical companies in the world committed to the management and treatment of gastrointestinal diseases, today will deliver a podium presentation of its research titled "Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs" during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023. The study led by Arun Jesudian, MD, Director of Inpatient Liver Services at NYPH/Weill Cornell, describes and compares healthcare resource utilization, including the rate of overt hepatic encephalopathy (OHE) hospitalizations, and costs during the 30-day period following an OHE hospitalization among patients who are treated with Xifaxan versus those who are not.

Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) came out with quarterly earnings of $0.52 per share, missing the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.72 per share a year ago.

Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates

First-Quarter revenues of $1.94 billion, up 1% reported and 4% organic1 Solid revenue growth across core products, led by Xifaxan with 7% reported growth Mid- and late-stage product pipeline advancing Bausch Health provides consolidated full-year guidance, and Bausch Health (excl. B+L) confirms 2023 guidance LAVAL, QC / ACCESSWIRE / May 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first-quarter 2023 financial results.

Bausch Health Announces First-Quarter 2023 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results. “Bausch + Lomb delivered a strong first quarter with continued high-quality growth across all three reporting segments and in most of our significant markets around the world,” said Brent Saunders, chairman and CEO, Baus.

Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

PDUFA Action Date is October 20, 2023 LAVAL, QC / ACCESSWIRE / May 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA) action date of October 20, 2023. If approved, IDP-126 has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris.

News for Bausch Health Companies Inc Stock (BHC)